LoginRegister

    Lupin Tarapur facility cautioned by USFDA post inspection

    Farhat NasimWritten by Farhat Nasim   |  

    "The company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between September 16 to September 20, 2019 as Official Action Indicated (OAI)," Lupin said in a filing to BSE.


    New Delhi: Drugmaker Lupin Ltd on Monday said the US health regulator has cautioned that its Tarapur manufacturing facility may be subject to regulatory actions.


    "The company has received a communication from the US FDA classifying the inspection conducted at its Tarapur manufacturing (API) facility between September 16 to September 20 2019 as Official Action Indicated (OAI)," Lupin said in a filing to BSE.


    Also Read: Lupin Tarapur API facility gets 3 observations from USFDA

    According to USFDA's definitions, Official Action Indicated means "objectionable conditions were found and regulatory administrative sanctions by USFDA are indicated" during inspections.


    The inspection at the Tarapur facility had closed with three observations.


    Also Read: Lupin gets 2 observations from USFDA for Nagpur facility
    LupinLupin inspectionlupin tarapur unitobjectionable conditionsOfficial Action IndicatedTarapur facilityUSFDAUSFDA inspection
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X